Drug-Coated Balloons (DCB): Sirolimus vs. Paclitaxel in De Novo Lesions in Small Vessels

The use of drug-coated balloons (DCB) offers the advantage of avoiding permanent stent implants, thus reducing the incidence of in-stent restenosis (ISR), neoatherosclerosis, and late in-stent thrombosis. Additionally, the use of DCB reduces the duration of dual antiplatelet therapy. Current evidence supports the use of DCB for ISR treatment (Class I) compared with drug-eluting stents<a href="https://solaci.org/en/2023/11/28/drug-coated-balloons-dcb-sirolimus-vs-paclitaxel-in-de-novo-lesions-in-small-vessels/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Stentless Strategy in ACS: Perfusion and Drug Coated Balloons

The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding.  However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>

TCT 2023 | ISAR-DESIRE 3: 10-Year Results

In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives. Despite current recommendations, treating ISR continues to be a challenge, and clinical<a href="https://solaci.org/en/2023/10/31/tct-2023-isar-desire-3-10-year-results/" title="Read more" >...</a>

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT).  A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at<a href="https://solaci.org/en/2023/10/30/tct-2023-compare-60-80-hbr-trial-2/" title="Read more" >...</a>

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was<a href="https://solaci.org/en/2023/10/30/tct-2023-t-pass-trial-asa-and-ticagrelor-in-acute-coronary-syndrome/" title="Read more" >...</a>

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

FLAME Study: FlowTriever Device in High-Risk Pulmonary Embolism

High-risk pulmonary embolism (HR-PE) is characterized by hemodynamic instability and marked deformation of the right ventricular (RV) fiber, which can lead to acute RV failure and hemodynamic collapse, with in-hospital mortality close to 25%. While guidelines recommend anticoagulant treatment followed by thrombolytics, these strategy carries a high risk of bleeding and is not suitable for<a href="https://solaci.org/en/2023/10/24/flame-study-flowtriever-device-in-high-risk-pulmonary-embolism/" title="Read more" >...</a>

OBSERVANT II: Post TAVR 30-Day and 6-Month Stroke Predictors

Despite stroke rate has declined since the early days of transcatheter aortic valve replacement (TAVR), it remains significant, reaching 1% to 3% 30 days after procedure. Since TAVR has seen a progressive expansion to the low risk and young populations, identifying risk factors in patient selection and management is crucial for us to prevent stroke. <a href="https://solaci.org/en/2023/10/20/observant-ii-post-tavr-30-day-and-6-month-stroke-predictors/" title="Read more" >...</a>

Left Main Coronary Artery PCI: In What Scenario Could We Not Use IVUS?

Lesions in the left main coronary artery (LMCA) continue to pose a significant challenge. The use of coronary imaging before percutaneous coronary implantation (PCI) has proven useful in analyzing the lesion, identifying the presence and location of calcification, and determining lesion length in the LMCA, the left anterior descending artery, and the circumflex artery. Various<a href="https://solaci.org/en/2023/10/10/left-main-coronary-artery-pci-in-what-scenario-could-we-not-use-ivus/" title="Read more" >...</a>

Resultado a 3 años luego de ATC con técnica de 2- stents vs Provisional stent por bifurcaciones complejas

Treatment and Gender-Based Outcomes for Coronary Bifurcation Stent Placement: Report from the e-ULTIMASTER Registry

Approximately 20% of all percutaneous coronary interventions (PCI) are performed on bifurcation lesions, which continue to pose a challenge in terms of strategy: how many stents to use, what is the most suitable strategy, and when to transition from a single stent to two during the procedure. Additionally, the use of two stents in these<a href="https://solaci.org/en/2023/10/06/treatment-and-gender-based-outcomes-for-coronary-bifurcation-stent-placement-report-from-the-e-ultimaster-registry/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

TriClip: Good Outcomes After a 2-Year Follow-up

Severe tricuspid regurgitation (TR) is an underestimated condition in healthcare systems. However, it is more common than believed, especially in individuals over 65 years of age.  This condition is linked to hospitalizations due to heart failure, mortality rates, and a progressive decline in quality of life.  Surgery to treat TR on its own is complicated,<a href="https://solaci.org/en/2023/10/04/triclip-good-outcomes-after-a-2-year-follow-up/" title="Read more" >...</a>